New Delhi, May 19 -- The country's top drug regulator, the Drugs Controller General of India (DCGI), has received 1,000 applications from micro, small and medium enterprise (MSME) medicine manufacturers detailing their plans to comply with good manufacturing practices (GMPs), according to two officials in the know.

With the application submission deadline ending on 11 May, there was a flurry of applications, given that failure to meet the criteria would result in measures, including show-cause notices, production-halt orders, suspension and even licence cancellation.

In 2023, the government notified the revised Schedule M of the Drugs and Cosmetics Act, 1945, to implement GMPs at par with the World Health Organization's (WHO) standards ...